(Total Views: 48)
Posted On: 12/04/2024 4:12:47 PM
Post# of 110
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Shares Insight on Breakthrough Drug Showing Promise for Neurodegenerative Diseases
Annovis Bio (NYSE: ANVS) was featured in an interview with Today’s Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University’s Institute for Population Health, joined host Jane King to discuss clinical trials of a new drug that is showing promise for the treatment of neurodegenerative diseases like Alzheimer’s (“AD”) and Parkinson’s (“PD”) and their impact on population health.
“We have over 7 million people with neurodegeneration in the United States, and it is a huge problem. We think of the patients, but we should also think of the caregivers, because the caregivers are very much affected by it too,” said Dr. Maccecchini, going on to explain that Annovis is seeking funding for the next phase trials of a drug in development that attacks the root causes of Alzheimer’s and Parkinson’s diseases and could help millions of patients.
“Most people have heard of plaque in Alzheimer’s and maybe Lewy bodies in Parkinson’s,” Dr. Maccecchini explained. “Our drug attacks plaque, tangles and Lewy bodies. It targets the toxic proteins that kill nerve cells in the brain, and it addresses more than one. If you have more than one toxic protein, just removing one still leaves others to kill nerve cells. Our drug actually protects nerve cells from dying.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS) was featured in an interview with Today’s Marketplace (“TMP”). The company’s Founder, President and CEO, Maria Maccecchini, PHD, and Scott Shipman, MD, MPH, Executive Director for Creighton University’s Institute for Population Health, joined host Jane King to discuss clinical trials of a new drug that is showing promise for the treatment of neurodegenerative diseases like Alzheimer’s (“AD”) and Parkinson’s (“PD”) and their impact on population health.
“We have over 7 million people with neurodegeneration in the United States, and it is a huge problem. We think of the patients, but we should also think of the caregivers, because the caregivers are very much affected by it too,” said Dr. Maccecchini, going on to explain that Annovis is seeking funding for the next phase trials of a drug in development that attacks the root causes of Alzheimer’s and Parkinson’s diseases and could help millions of patients.
“Most people have heard of plaque in Alzheimer’s and maybe Lewy bodies in Parkinson’s,” Dr. Maccecchini explained. “Our drug attacks plaque, tangles and Lewy bodies. It targets the toxic proteins that kill nerve cells in the brain, and it addresses more than one. If you have more than one toxic protein, just removing one still leaves others to kill nerve cells. Our drug actually protects nerve cells from dying.”
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Scroll down for more posts ▼
